Search research articles
Contact Us
Filters
Showing results (1-10 of 4) with videos related to
Page
of 1
Sort By:
Journal of Applied Microbiology
|
April 24, 2007
In vivo gene delivery and expression by bacteriophage lambda vectors
H A Lankes, C N Zanghi, K Santos, et al.
Gynecologic Oncology
|
January 17, 2013
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study
R J Schilder, M W Sill, H A Lankes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2016
A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)
P H Thaker, R Salani, W E Brady, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study
B J Monk, M F Brady, C Aghajanian, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 4) with videos related to
Sort By:
Page
of 1
Journal of Applied Microbiology
|
April 24, 2007
In vivo gene delivery and expression by bacteriophage lambda vectors
H A Lankes, C N Zanghi, K Santos, et al.
Gynecologic Oncology
|
January 17, 2013
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study
R J Schilder, M W Sill, H A Lankes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2016
A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)
P H Thaker, R Salani, W E Brady, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study
B J Monk, M F Brady, C Aghajanian, et al.
Page
of 1